Meeting the Demands of Modern Biopharmaceuticals: Exploring Single Use Bioprocessing Solutions
MarketsandMarkets™
has added a new report titled, ‘Global Single use Bioprocessing Market’ in its vast database of research reports. The
Global Single-use Bioprocessing Market is thoroughly analyzed in this report,
providing valuable insights into its current landscape and future growth
prospects. The report covers the forecast period of 2021 to 2026 and offers a
comprehensive overview of the market by utilizing a meticulous approach that
involves studying, synthesizing, and consolidating data from multiple reliable
sources. With the aim of accurately determining the market size, the report
presents a detailed analysis of key factors and trends driving the growth of
the single-use bioprocessing market. The findings of this report serve as a
valuable resource for industry stakeholders, researchers, and decision-makers
seeking to understand the dynamics of the global single-use bioprocessing
market and make informed business decisions.
The report is
helpful to everyone, right from an expert, professional, analyst, employee to a
manager. This report contains statistical data that enables the reader to have
a detailed summary and the overall insights, which can be applied in the decision-making
process, taking into consideration the core and crucial business areas. The
report also contains some illustrations and presentations, in the form of
charts, graphs, and tables, along with qualitative and quantitative data, so as
to understand and gain insights. The report also helps the readers by availing
the ready-to-access analytical data provided by the industry experts.
Download a PDF
Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297
The report
"Single use Bioprocessing Market Size, Growth by Product (Media Bags and
containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture,
Mixing, Storage, Filtration, Purification), End User (Biopharma Companies,
CROs, CMOs) - Global Forecast 2026", is projected to reach USD 20.8
billion by 2026, at a CAGR of 20.5%.
The single-use
bioprocessing market is highly consolidated with majority of the market share
taken up by key players such as Thermo Fisher Scientific (US), Danaher
Corporation (US), Sartorius Stedim Biotech S.A. (France), and Merck KGaA
(Germany). The key players in this market are increasingly focusing on
strategic expansions, partnerships, and product approvals to expand their
manufacturing capabilities and increase market presence.
This study
categorizes the global single use bioprocessing market to forecast revenue and
analyze trends in each of the following submarkets:
By Product
·
Single-use
media bags and containers
·
Single-use
assemblies
·
Single-use
bioreactors
·
Disposable
mixers
·
Other
products
By Application
·
Filtration
·
Storage
·
Cell
culture
·
Mixing
·
Purification
By End user
·
Biopharmaceutical
& Pharmaceutical companies
·
Contract
Research Organizations and contract manufacturing organizations (CROs &
CMOs)
·
Academic
& Research institutes
Some of the key
geographies mentioned in this report include:
·
North
America (U.S and Canada and rest of North America)
·
Europe
(Germany, France, Italy and Rest of Europe)
·
Asia-Pacific
(China, Japan, India, South Korea and Rest of Asia-Pacific)
·
LAMEA
(Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)
Hypothetic
Challenges of Single use Bioprocessing Market in Near Future:
·
Regulatory Challenges: As the use of single-use bioprocessing
technologies becomes more widespread, regulatory bodies may need to develop new
guidelines and standards for their use. This could create uncertainty and delay
in the adoption of these technologies.
·
Supply Chain Disruptions: The COVID-19 pandemic has
highlighted the fragility of global supply chains. If there are disruptions in
the supply of raw materials or components needed for single-use bioprocessing
systems, this could lead to delays and increased costs for manufacturers.
·
Environmental Concerns: While single-use bioprocessing
systems offer several advantages over traditional stainless-steel systems, they
also generate more waste. There may be increasing pressure from regulators and consumers
to reduce waste and increase sustainability in the biopharmaceutical industry.
·
Cost: While single-use bioprocessing systems offer several
advantages, they can be more expensive than traditional stainless-steel
systems. This may limit their adoption in certain markets or by smaller
biopharmaceutical companies.
·
Technology Limitations: While single-use bioprocessing
systems have advanced significantly in recent years, there may still be
limitations in their performance and scalability for certain applications. This
could limit their adoption in certain markets or by certain biopharmaceutical
companies.
Top 3 Use Cases
of Single use Bioprocessing Market:
·
Cell Culture: Single-use bioreactors and other disposable
technologies are widely used in cell culture for the production of biologics,
such as monoclonal antibodies and recombinant proteins. These systems offer
several advantages over traditional stainless-steel systems, including reduced
cleaning and validation time, increased flexibility, and reduced risk of
cross-contamination.
·
Downstream Processing: Single-use chromatography systems and
other disposable technologies are used in downstream processing to purify and
concentrate biologic products. These systems offer several advantages over
traditional stainless-steel systems, including reduced cleaning and validation
time, increased flexibility, and reduced risk of cross-contamination.
·
Vaccine Production: Single-use bioprocessing technologies are
increasingly being used for the production of vaccines. These technologies
offer several advantages over traditional stainless-steel systems, including
reduced cleaning and validation time, increased flexibility, and reduced risk
of cross-contamination. Additionally, single-use bioprocessing systems are
well-suited for the rapid production of vaccines in response to outbreaks or
pandemics.
Recent
Developments:
·
In March 2020, Danaher acquired the Biopharma business from
General Electric Company's Life Sciences division. The business is called
Cytiva and is a standalone operating company within Danaher's Life Sciences
segment.
·
In September 2020, Thermo Fisher Scientific invested more
than USD 475 million in new capabilities at its St. Louis site to expand
biologics development and manufacturing, cell and gene therapy capabilities,
and drug product development capabilities.
Content Source:
https://www.marketsandmarkets.com/PressReleases/single-use-bioprocessing.asp
https://www.marketsandmarkets.com/ResearchInsight/single-use-bioprocessing-market.asp
Related Reports:

Comments
Post a Comment